welcome

We are glad to welcome you to our website

This depends on your condition and whether or not you are taking any other medicines. The usual adult dose is one 5mg tablet two to three times per day. Your doctor may reduce this dosage depending on your general condition. If you do not understand the instructions on the bottle, ask your doctor or pharmacist for help. Oxybutynin Sandoz helps control your condition, but does not cure it.

Therefore, you must take Oxybutynin Sandoz every day. Immediately telephone your doctor or the Poisons Information Centre (telephone 13 11 26) for advice, or go to Accident and Emergency at your nearest hospital, if you think that you or anyone else may have taken too much Oxybutynin Sandoz.

If you are about to be started on any new medicine, remind your doctor and pharmacist that you are taking Oxybutynin Sandoz. If you are going to have surgery that needs a general anaesthetic, tell your doctor or dentist that you are taking Oxybutynin Sandoz. Do not give Oxybutynin Sandoz to anyone else, even if they have the same condition as you. Do not take Oxybutynin Sandoz to treat any other complaints unless your doctor or pharmacist tells you to.

Oxybutynin Sandoz may make you sweat less, causing your body temperature to rise. Take extra care to avoid becoming overheated during exercise or hot weather, since overheating may result in heat stroke.

Be careful driving or operating machinery until you know how Oxybutynin Sandoz affects you. This medicine may cause drowsiness or blurred vision in some people. If you have any of these symptoms, do not drive a car, operate machinery, or do anything else that could be dangerous.

Tell your doctor or pharmacist as soon as possible if you do not feel well while you are taking Oxybutynin Sandoz. Oxybutynin Sandoz helps most people, but it may have unwanted side effects in a few people. If you are elderly, you may be especially sensitive to the effects of Oxybutynin Sandoz. This may increase the chance of side effects during treatment.

Tell your doctor or pharmacist if you notice any of the following and they worry you:These may be serious side effects. If any of the following happen, tell your doctor or pharmacist immediately or go to Accident and Emergency at your nearest hospital:Tell your doctor or pharmacist if you notice anything that is making you feel unwell.

Do not store Oxybutynin Sandoz or any other medicine in the bathroom or near a sink. If your doctor or pharmacist tells you to stop taking this medicine or the expiry date has passed, ask your pharmacist what to do with any medicine that is left over. Sandoz Pty LtdABN 60 075 449 55354 Waterloo RoadMacquarie Park, NSW 2113AustraliaTel: 1800 634 500Oxybutynin hydrochloride.

Calcium stearate, microcrystalline cellulose, anhydrous lactose and brilliant blue FCF aluminium lake. Chemical name: 4-diethylamino-2- butynyl phenylcyclohexylglycolate hydrochloride. It is a white crystalline solid, which is readily soluble in water and acids, but relatively insoluble in alkalis. Oxybutynin hydrochloride exerts a direct antispasmodic effect on smooth muscle and inhibits the muscarinic action of acetylcholine on smooth muscle.

Oxybutynin hydrochloride exhibits four to ten times the antispasmodic potency of atropine, but only one-fifth of the anticholinergic activity of atropine on the rabbit detrusor muscle. No blocking effects occur at skeletal neuromuscular junctions or autonomic ganglia (antinicotinic effects). Oxybutynin Sandoz relaxes bladder smooth muscle. In patients with conditions characterised by involuntary bladder contractions, cystometric studies have demonstrated that Oxybutynin Sandoz increases bladder (vesical) capacity, diminishes the frequency of uninhibited contractions of the detrusor muscle, and delays the initial desire to void.

Oxybutynin Sandoz thus decreases urgency and the frequency of both incontinent episodes and voluntary urination. Oxybutynin hydrochloride is readily absorbed (peak plasma concentration in approx. Oxybutynin hydrochloride undergoes significant first pass metabolism. Very little unchanged drug or metabolites are detected in the urine suggesting the importance of biliary excretion. Oxybutynin Sandoz is contraindicated in patients with increased intraocular pressure associated with angle closure (glaucoma) or shallow anterior chamber since anticholinergic drugs may aggravate this condition.

It is also contraindicated in partial or complete obstruction of the gastrointestinal tract, paralytic ileus, intestinal atony of the elderly or debilitated patient, megacolon, toxic megacolon complicating ulcerative colitis, severe colitis, and myasthenia gravis. It is contraindicated in patients with obstructive uropathy and in patients with unstable cardiovascular status in acute haemorrhage. Oxybutynin Sandoz is contraindicated in patients who have demonstrated hypersensitivity to the product.

Avoid dosage in high environmental temperatures and excessive exercise in high temperatures since oxybutynin hydrochloride administered under these conditions can cause heat prostration (fever and heat stroke due to decreased sweating). Diarrhoea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy.

In this instance, treatment with Oxybutynin Sandoz would be inappropriate and possibly harmful. Oxybutynin may produce drowsiness or blurred vision. The patient should be cautioned regarding activities requiring mental alertness, such as operating a motor vehicle or other machinery or performing hazardous work while taking this drug.

Alcohol or other sedative drugs may enhance the drowsiness caused by Oxybutynin Sandoz. Pretreatment examinations should normally include cystometry, and other appropriate diagnostic procedures. Cystometry should be repeated at appropriate intervals to evaluate response to therapy. The appropriate antibiotic therapy should be instituted in the presence of infection.

Oxybutynin should be used with caution and only where there is evidence of detrusor overactivity in the elderly. Use with caution in patients with autonomic neuropathy, hepatic or renal disease. Administration of oxybutynin in large doses to patients with ulcerative colitis may suppress intestinal motility to the point of producing a paralytic ileus and precipitate or aggravate toxic megacolon, a serious complication of the disease.

Oxybutynin may aggravate cognitive disorders, symptoms of prostatic hypertrophy and tachycardia (thus be cautious in case of hyperthyroidism, coronary heart disease, congestive heart failure, cardiac arrhythmias, and hypertension).

The drug should be administered with caution to patients with hiatus hernia associated with reflux esophagitis since anticholinergic drugs may aggravate this condition. However, the incidence of abortion was slightly increased at the highest dose level in rabbits. The relevance of these observations were difficult to access.

The safety of oxybutynin hydrochloride in women who are or who may become pregnant has not been established, it should be given only when the potential benefits outweigh the possible hazards. There is some evidence from animal studies that oxybutynin or its metabolites are excreted in milk. Oxybutynin Sandoz is not recommended for administration to a nursing woman. Oxybutynin Sandoz should be used with caution in children as they may be more sensitive to the effects of the product.

Oxybutynin should not be used in children with enuresis without definitive evidence of detrusor overactivity. As there is insufficient clinical data for children under age five, Oxybutynin Sandoz is not recommended for this age group. The safety and efficacy of Oxybutynin Sandoz administration have been demonstrated for children five years of age and older (see Dosage and Administration).

The anticholinergic effect of Oxybutynin Sandoz is enhanced by its concomitant use with other agents with anticholinergic properties. These include the phenothiazines, butyrophenones, L-dopa, digitalis, tricyclic antidepressants, amantadine, scopolamine and some of the antihistamines. By reducing gastric motility, oxybutynin may affect the absorption of other drugs. Oxybutynin, as an anticholinergic agent, may antagonise the effect of prokinetic therapies.

Following administration of Oxybutynin Sandoz, the symptoms that can be associated with the use of other anticholinergic drugs may occur. Not known: palpitations, cardiac arrhythmia, tachycardia, vasodilation.